D-0896-2023 Class III Ongoing
FDA drug recall D-0896-2023 was initiated by Vivus, Inc. on Jun 23, 2023 and is designated Class III. Reason for recall: Failed Stability Specifications The recall status is ongoing. Affected quantity: 4240 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 19, 2023
- Initiation Date
- Jun 23, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4240 bottles
Product description
PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC: N3 62541-401-10 5, NDC 62541-401-10,
Reason for recall
Failed Stability Specifications
Distribution pattern
Nationwide within the United States
Code information
Lot #: 102101, Exp: 31 July 2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0896-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026